Insmed discontinues hidradenitis suppurativa program after failed trial

April 7, 2026 4:01 PM

Insmed Incorporated (NASDAQ: INSM) announced that its Phase 2b CEDAR study evaluating brensocatib for hidradenitis suppurativa failed to meet primary ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found